Turnstone Biologics Corp. is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte therapy. Turnstone Biologics Corp. is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $19.31M |
| Net Income (Most Recent Fiscal Year) | $-70.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -162.79% |
| Return on Assets (Trailing 12 Months) | -124.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.86 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.51 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.73 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 23.14M |
| Free Float | 15.71M |
| Market Capitalization | $7.48M |
| Average Volume (Last 20 Days) | 0.09M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 32.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |